Implications of new technology for infectious diseases practice.
New assays for the diagnosis of infectious diseases--particularly those that use molecular technologies--will revolutionize infectious diseases practices, but the fulfillment of the promise is several years away. Problems with currently available molecular assays include a lack of knowledge about the extent of microbial nucleic acid in "normal" hosts, concentration of agent material in small volume samples, lack of microbiologist expertise, lack of adequate reimbursement, and difficulty with validation based on conventional methods. Clinicians must appreciate the shortcomings of new technology to use it effectively and appropriately. However, we are realizing tangible progress in our ability to detect new etiological agents; the availability of rapid, accurate diagnostic tests for previously difficult infections; and advances into new, human response-based paradigms for diagnostic testing.
Baron
Ellen Jo
EJ
Department of Pathology, Division of Infectious Diseases and Geographic Medicine, Stanford University Medical Center, Stanford, CA 94305, USA. ejbaron@stanford.edu
D001419:Bacteria / Q000235:genetics / Q000302:isolation & purification; D003141:Communicable Diseases / Q000175:diagnosis*; D015342:DNA Probes; D006801:Humans; D046228:Microarray Analysis; D008828:Microbiological Techniques; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D021141:Nucleic Acid Amplification Techniques / Q000379:methods; D016133:Polymerase Chain Reaction / Q000379:methods; D012680:Sensitivity and Specificity; D014780:Viruses / Q000235:genetics / Q000302:isolation & purification
D015342:DNA Probes